Bariatric surgery for extreme adolescent obesity: Indications, outcomes, and physiologic effects on the gut-brain axis

Pathophysiology

Volumn 15, Issue 2, 2008, Pages 135-146

  Xanthakos, Stavra A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Adolescent obesity; Bariatric surgery; Gastric bypass; Ghrelin; GLP 1; Obesity; PYY

Indexed keywords

CHOLECYSTOKININ; DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY; PEPTIDE YY [3-36];

ADOLESCENT DISEASE; BARIATRIC SURGERY; DISEASE SEVERITY; FOOD INTAKE; GASTRECTOMY; GASTRIC BANDING; HUMAN; OBESITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; ROUX Y ANASTOMOSIS; SATIETY; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

EID: 48449084351     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2008.04.005     Document Type: Review

References (139)

1. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch. Intern. Med. 163 (2003) 2146-2148
2. Flegal K.M., Carroll M.D., Ogden C.L., and Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (2002) 1723-1727
3. Hedley A.A., Ogden C.L., Johnson C.L., Carroll M.D., Curtin L.R., and Flegal K.M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291 (2004) 2847-2850
4. Freedman D.S., Mei Z., Srinivasan S.R., Berenson G.S., and Dietz W.H. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J. Pediatr. 150 (2007) 12-17 e12
5. Zeller M., Kirk S., Claytor R., Khoury P., Grieme J., Santangelo M., and Daniels S. Predictors of attrition from a pediatric weight management program. J. Pediatr. 144 (2004) 466-470
6. Levine M.D., Ringham R.M., Kalarchian M.A., Wisniewski L., and Marcus M.D. Is family-based behavioral weight control appropriate for severe pediatric obesity?. Int. J. Eat. Disord. 30 (2001) 318-328
7. Inge T.H., Xanthakos S.A., and Zeller M.H. Bariatric surgery for pediatric extreme obesity: now or later?. Int. J. Obes. (Lond.) 31 (2007) 1-14
8. Tsai W., Inge T., and Burd R. Adolescent bariatric surgery: recent national trends in utilization and in hospital outcomes. Arch. Pediatr. Adolesc. Med. 161 (2007) 217-221
9. Xanthakos S.A., Daniels S.R., and Inge T.H. Bariatric surgery in adolescents: an update. Adolesc. Med. Clin. 17 (2006) 589-612 (abstract x)
10. Inge T.H., Krebs N.F., Garcia V.F., Skelton J.A., Guice K.S., Strauss R.S., Albanese C.T., Brandt M.L., Hammer L.D., Harmon C.M., Kane T.D., Klish W.J., Oldham K.T., Rudolph C.D., Helmrath M.A., Donovan E., and Daniels S.R. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics 114 (2004) 217-223
11. Inge T.H., Garcia V., Daniels S., Langford L., Kirk S., Roehrig H., Amin R., Zeller M., and Higa K. A multidisciplinary approach to the adolescent bariatric surgical patient. J. Pediatr. Surg. 39 (2004) 442-447 (discussion 446-447)
12. Xanthakos S.A., and Inge T.H. Extreme pediatric obesity: weighing the health dangers. J. Pediatr. 150 (2007) 3-5
13. Randolph J.G., Weintraub W.H., and Rigg A. Jejunoileal bypass for morbid obesity in adolescents. J. Pediatr. Surg. 9 (1974) 341-345
14. Organ Jr. C.H., Kessler E., and Lane M. Long-term results of jejunoileal bypass in the young. Am. Surg. 50 (1984) 589-593
15. Hocking M.P., Duerson M.C., O'Leary J.P., and Woodward E.R. Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases. N. Engl. J. Med. 308 (1983) 995-999
16. Silber T., Randolph J., and Robbins S. Long-term morbidity and mortality in morbidly obese adolescents after jejunoileal bypass. J. Pediatr. 108 (1986) 318-322
17. 2) compared with gastric bypass. Ann. Surg. 244 (2006) 611-619
18. Mason E.E., Scott D.H., Doherty C., Cullen J.J., Rodriguez E.M., Maher J.W., and Soper R.T. Vertical banded gastroplasty in the severely obese under age twenty-one. Obes. Surg. 5 (1995) 23-33
19. Rand C.S., and Macgregor A.M. Adolescents having obesity surgery: a 6-year follow-up. South Med. J. 87 (1994) 1208-1213
20. Anderson A.E., Soper R.T., and Scott D.H. Gastric bypass for morbid obesity in children and adolescents. J. Pediatr. Surg. 15 (1980) 876-881
21. Xanthakos S.A., and Inge T.H. Nutritional consequences of bariatric surgery. Curr. Opin. Clin. Nutr. Metab. Care 9 (2006) 489-496
22. Lawson M.L., Kirk S., Mitchell T., Chen M.K., Loux T.J., Daniels S.R., Harmon C.M., Clements R.H., Garcia V.F., and Inge T.H. One-year outcomes of Roux-en-Y gastric bypass for morbidly obese adolescents: a multicenter study from the Pediatric Bariatric Study Group. J. Pediatr. Surg. 41 (2006) 137-143 (discussion 137-143)
23. Strauss R.S., Bradley L.J., and Brolin R.E. Gastric bypass surgery in adolescents with morbid obesity. J. Pediatr. 138 (2001) 499-504
24. Sugerman H.J., Sugerman E.L., DeMaria E.J., Kellum J.M., Kennedy C., Mowery Y., and Wolfe L.G. Bariatric surgery for severely obese adolescents. J. Gastrointest. Surg. 7 (2003) 102-107 (discussion 107-108)
25. Kalra M., Inge T., Garcia V., Daniels S., Lawson L., Curti R., Cohen A., and Amin R. Obstructive sleep apnea in extremely overweight adolescents undergoing bariatric surgery. Obes. Res. 13 (2005) 1175-1179
26. Fielding G.A., and Duncombe J.E. Laparoscopic adjustable gastric banding in severely obese adolescents. Surg. Obes. Relat. Dis. 1 (2005) 399-405 (discussion 405-397)
27. Dolan K., and Fielding G. A comparison of laparoscopic adjustable gastric banding in adolescents and adults. Surg. Endosc. 18 (2004) 45-47
28. Dillard III B.E., Gorodner V., Galvani C., Holterman M., Browne A., Gallo A., Horgan S., and Le Holterman A.X. Initial experience with the adjustable gastric band in morbidly obese US adolescents and recommendations for further investigation. J. Pediatr. Gastroenterol. Nutr. 45 (2007) 240-246
29. Chapman A.E., Kiroff G., Game P., Foster B., O'Brien P., Ham J., and Maddern G.J. Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic literature review. Surgery 135 (2004) 326-351
30. Sjostrom L., Lindroos A.K., Peltonen M., Torgerson J., Bouchard C., Carlsson B., Dahlgren S., Larsson B., Narbro K., Sjostrom C.D., Sullivan M., and Wedel H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351 (2004) 2683-2693
31. Lee C.M., Cirangle P.T., and Jossart G.H. Vertical gastrectomy for morbid obesity in 216 patients: report of two-year results. Surg. Endosc. 21 (2007) 1810-1816
32. Himpens J., Dapri G., and Cadiere G.B. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes. Surg. 16 (2006) 1450-1456
33. Maggard M.A., Shugarman L.R., Suttorp M., Maglione M., Sugerman H.J., Livingston E.H., Nguyen N.T., Li Z., Mojica W.A., Hilton L., Rhodes S., Morton S.C., and Shekelle P.G. Meta-analysis: surgical treatment of obesity. Ann. Intern. Med. 142 (2005) 547-559
34. Brolin R.E., Gorman J.H., Gorman R.C., Petschenik A.J., Bradley L.J., Kenler H.A., and Cody R.P. Are vitamin B12 and folate deficiency clinically important after Roux-en-Y gastric bypass?. J. Gastrointest. Surg. 2 (1998) 436-442
35. Rabkin R.A., Rabkin J.M., Metcalf B., Lazo M., Rossi M., and Lehman-Becker L.B. Nutritional markers following duodenal switch for morbid obesity. Obes. Surg. 14 (2004) 84-90
36. Fujioka K. Follow-up of nutritional and metabolic problems after bariatric surgery. Diabetes Care 28 (2005) 481-484
37. Towbin A., Inge T.H., Garcia V.F., Roehrig H.R., Clements R.H., Harmon C.M., and Daniels S.R. Beriberi after gastric bypass surgery in adolescence. J. Pediatr. 145 (2004) 263-267
38. Adamo M., Raizada M.K., and LeRoith D. Insulin and insulin-like growth factor receptors in the nervous system. Mol. Neurobiol. 3 (1989) 71-100
39. Antin J., Gibbs J., Holt J., Young R.C., and Smith G.P. Cholecystokinin elicits the complete behavioral sequence of satiety in rats. J. Comp. Physiol. Psychol. 89 (1975) 784-790
40. Strader A.D., and Woods S.C. Gastrointestinal hormones and food intake. Gastroenterology 128 (2005) 175-191
41. Tschop M., Smiley D.L., and Heiman M.L. Ghrelin induces adiposity in rodents. Nature 407 (2000) 908-913
42. Cummings D.E., and Overduin J. Gastrointestinal regulation of food intake. J. Clin. Invest. 117 (2007) 13-23
43. Dornonville de la Cour C., Bjorkqvist M., Sandvik A.K., Bakke I., Zhao C.M., Chen D., and Hakanson R. A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control. Regul. Pept. 99 (2001) 141-150
44. Wierup N., Bjorkqvist M., Westrom B., Pierzynowski S., Sundler F., and Sjolund K. Ghrelin and motilin are cosecreted from a prominent endocrine cell population in the small intestine. J. Clin. Endocrinol. Metab. 92 (2007) 3573-3581
45. Ariyasu H., Takaya K., Tagami T., Ogawa Y., Hosoda K., Akamizu T., Suda M., Koh T., Natsui K., Toyooka S., Shirakami G., Usui T., Shimatsu A., Doi K., Hosoda H., Kojima M., Kangawa K., and Nakao K. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. 86 (2001) 4753-4758
46. Popovic V., Miljic D., Pekic S., Pesko P., Djurovic M., Doknic M., Damjanovic S., Micic D., Cvijovic G., Glodic J., Dieguez C., and Casanueva F.F. Low plasma ghrelin level in gastrectomized patients is accompanied by enhanced sensitivity to the ghrelin-induced growth hormone release. J. Clin. Endocrinol. Metab. 90 (2005) 2187-2191
47. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402 (1999) 656-660
48. Guan X.M., Yu H., Palyha O.C., McKee K.K., Feighner S.D., Sirinathsinghji D.J., Smith R.G., Van der Ploeg L.H., and Howard A.D. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res. Mol. Brain Res. 48 (1997) 23-29
49. Adeghate E., and Ponery A.S. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J. Neuroendocrinol. 14 (2002) 555-560
50. Nagaya N., Uematsu M., Kojima M., Ikeda Y., Yoshihara F., Shimizu W., Hosoda H., Hirota Y., Ishida H., Mori H., and Kangawa K. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 104 (2001) 1430-1435
51. Dixit V.D., and Taub D.D. Ghrelin and immunity: a young player in an old field. Exp. Gerontol. 40 (2005) 900-910
52. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., and Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50 (2001) 1714-1719
53. Tschop M., Wawarta R., Riepl R.L., Friedrich S., Bidlingmaier M., Landgraf R., and Folwaczny C. Post-prandial decrease of circulating human ghrelin levels. J. Endocrinol. Invest. 24 (2001) RC19-RC21
54. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., Dhillo W.S., Ghatei M.A., and Bloom S.R. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86 (2001) 5992
55. Wren A.M., Small C.J., Abbott C.R., Dhillo W.S., Seal L.J., Cohen M.A., Batterham R.L., Taheri S., Stanley S.A., Ghatei M.A., and Bloom S.R. Ghrelin causes hyperphagia and obesity in rats. Diabetes 50 (2001) 2540-2547
56. Nakazato M., Murakami N., Date Y., Kojima M., Matsuo H., Kangawa K., and Matsukura S. A role for ghrelin in the central regulation of feeding. Nature 409 (2001) 194-198
57. Wortley K.E., del Rincon J.P., Murray J.D., Garcia K., Iida K., Thorner M.O., and Sleeman M.W. Absence of ghrelin protects against early-onset obesity. J. Clin. Invest. 115 (2005) 3573-3578
58. Chen H.Y., Trumbauer M.E., Chen A.S., Weingarth D.T., Adams J.R., Frazier E.G., Shen Z., Marsh D.J., Feighner S.D., Guan X.M., Ye Z., Nargund R.P., Smith R.G., Van der Ploeg L.H., Howard A.D., MacNeil D.J., and Qian S. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 145 (2004) 2607-2612
59. Hewson A.K., Tung L.Y., Connell D.W., Tookman L., and Dickson S.L. The rat arcuate nucleus integrates peripheral signals provided by leptin, insulin, and a ghrelin mimetic. Diabetes 51 (2002) 3412-3419
60. Spiegelman B.M., and Flier J.S. Obesity and the regulation of energy balance. Cell 104 (2001) 531-543
61. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., Kangawa K., and Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123 (2002) 1120-1128
62. Chelikani P.K., Haver A.C., and Reidelberger R.D. Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY(3-36) on food intake and gastric emptying in rats. Diabetes 55 (2006) 3038-3046
63. Masuda Y., Tanaka T., Inomata N., Ohnuma N., Tanaka S., Itoh Z., Hosoda H., Kojima M., and Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 276 (2000) 905-908
64. Levin F., Edholm T., Ehrstrom M., Wallin B., Schmidt P.T., Kirchgessner A.M., Hilsted L.M., Hellstrom P.M., and Naslund E. Effect of peripherally administered ghrelin on gastric emptying and acid secretion in the rat. Regul. Pept. 131 (2005) 59-65
65. Thompson N.M., Gill D.A., Davies R., Loveridge N., Houston P.A., Robinson I.C., and Wells T. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 145 (2004) 234-242
66. Ott V., Fasshauer M., Dalski A., Meier B., Perwitz N., Klein H.H., Tschop M., and Klein J. Direct peripheral effects of ghrelin include suppression of adiponectin expression. Horm. Metab. Res. 34 (2002) 640-645
67. Tschop M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., and Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001) 707-709
68. English P.J., Ghatei M.A., Malik I.A., Bloom S.R., and Wilding J.P. Food fails to suppress ghrelin levels in obese humans. J. Clin. Endocrinol. Metab. 87 (2002) 2984
69. Cummings D.E., Weigle D.S., Frayo R.S., Breen P.A., Ma M.K., Dellinger E.P., and Purnell J.Q. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346 (2002) 1623-1630
70. Hansen T.K., Dall R., Hosoda H., Kojima M., Kangawa K., Christiansen J.S., and Jorgensen J.O. Weight loss increases circulating levels of ghrelin in human obesity. Clin. Endocrinol. (Oxf.) 56 (2002) 203-206
71. Reinehr T., de Sousa G., and Roth C.L. Obestatin and ghrelin levels in obese children and adolescents before and after reduction of overweight. Clin. Endocrinol. 68 (2008) 304-310
72. Reinehr T., Roth C.L., Alexy U., Kersting M., Kiess W., and Andler W. Ghrelin levels before and after reduction of overweight due to a low-fat high-carbohydrate diet in obese children and adolescents. Int. J. Obes. (Lond.) 29 (2005) 362-368
73. Fruhbeck G., Diez Caballero A., and Gil M.J. Fundus functionality and ghrelin concentrations after bariatric surgery. N. Engl. J. Med. 350 (2004) 308-309
74. Fruhbeck G., Rotellar F., Hernandez-Lizoain J.L., Gil M.J., Gomez-Ambrosi J., Salvador J., and Cienfuegos J.A. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes. Surg. 14 (2004) 1208-1215
75. Korner J., Bessler M., Cirilo L.J., Conwell I.M., Daud A., Restuccia N.L., and Wardlaw S.L. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J. Clin. Endocrinol. Metab. 90 (2005) 359-365
76. Tritos N.A., Mun E., Bertkau A., Grayson R., Maratos-Flier E., and Goldfine A. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes. Res. 11 (2003) 919-924
77. Korner J., Inabnet W., Conwell I.M., Taveras C., Daud A., Olivero-Rivera L., Restuccia N.L., and Bessler M. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 14 (2006) 1553-1561
78. Inge T.H., Pfluger P., Zeller M., Rose S.R., Burget L., Sundararajan S., Daniels S.R., and Tschop M.H. Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat. Clin. Pract. Endocrinol. Metab. 3 (2007) 606-609
79. Holdstock C., Engstrom B.E., Ohrvall M., Lind L., Sundbom M., and Karlsson F.A. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J. Clin. Endocrinol. Metab. 88 (2003) 3177-3183
80. Sundbom M., Holdstock C., Engstrom B.E., and Karlsson F.A. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality?. Obes. Surg. 17 (2007) 304-310
81. Faraj M., Havel P.J., Phelis S., Blank D., Sniderman A.D., and Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 88 (2003) 1594-1602
82. Stoeckli R., Chanda R., Langer I., and Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes. Res. 12 (2004) 346-350
83. Nijhuis J., van Dielen F.M., Buurman W.A., and Greve J.W. Ghrelin, leptin and insulin levels after restrictive surgery: a 2-year follow-up study. Obes. Surg. 14 (2004) 783-787
84. le Roux C.W., Aylwin S.J., Batterham R.L., Borg C.M., Coyle F., Prasad V., Shurey S., Ghatei M.A., Patel A.G., and Bloom S.R. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg. 243 (2006) 108-114
85. Langer F.B., Reza Hoda M.A., Bohdjalian A., Felberbauer F.X., Zacherl J., Wenzl E., Schindler K., Luger A., Ludvik B., and Prager G. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes. Surg. 15 (2005) 1024-1029
86. Cohen R., Uzzan B., Bihan H., Khochtali I., Reach G., and Catheline J.M. Ghrelin levels and sleeve gastrectomy in super-super-obesity. Obes. Surg. 15 (2005) 1501-1502
87. Christou N.V., Look D., and McLean A.P. Pre- and post-prandial plasma ghrelin levels do not correlate with satiety or failure to achieve a successful outcome after Roux-en-Y gastric bypass. Obes. Surg. 15 (2005) 1017-1023
88. Adrian T.E., Bacarese-Hamilton A.J., Smith H.A., Chohan P., Manolas K.J., and Bloom S.R. Distribution and postprandial release of porcine peptide YY. J. Endocrinol. 113 (1987) 11-14
89. Anini Y., Fu-Cheng X., Cuber J.C., Kervran A., Chariot J., and Roz C. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch. 438 (1999) 299-306
90. Mentlein R., Dahms P., Grandt D., and Kruger R. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul. Pept. 49 (1993) 133-144
91. Larhammar D. Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 65 (1996) 165-174
92. Grandt D., Schimiczek M., Beglinger C., Layer P., Goebell H., Eysselein V.E., and Reeve Jr. J.R. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul. Pept. 51 (1994) 151-159
93. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., Wren A.M., Brynes A.E., Low M.J., Ghatei M.A., Cone R.D., and Bloom S.R. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
94. Chen X., DiMaggio D.A., Han S.P., and Westfall T.C. Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors. Am. J. Physiol. 273 (1997) H1737-H1744
95. Naveilhan P., Hassani H., Canals J.M., Ekstrand A.J., Larefalk A., Chhajlani V., Arenas E., Gedda K., Svensson L., Thoren P., and Ernfors P. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat. Med. 5 (1999) 1188-1193
96. Boggiano M.M., Chandler P.C., Viana J.B., Oswald K.D., Maldonado C.R., and Wauford P.K. Combined dieting and stress evoke exaggerated responses to opioids in binge-eating rats. Behav. Neurosci. 119 (2005) 1207-1214
97. Morley J.E., Levine A.S., Grace M., and Kneip J. Peptide YY (PYY), a potent orexigenic agent. Brain Res. 341 (1985) 200-203
98. Stanley B.G., Daniel D.R., Chin A.S., and Leibowitz S.F. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 6 (1985) 1205-1211
99. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., Ghatei M.A., and Bloom S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 349 (2003) 941-948
100. Batterham R.L., Le Roux C.W., Cohen M.A., Park A.J., Ellis S.M., Patterson M., Frost G.S., Ghatei M.A., and Bloom S.R. Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab. 88 (2003) 3989-3992
101. Tschop M., Castaneda T.R., Joost H.G., Thone-Reineke C., Ortmann S., Klaus S., Hagan M.M., Chandler P.C., Oswald K.D., Benoit S.C., Seeley R.J., Kinzig K.P., Moran T.H., Beck-sickinger A.G., Koglin N., Rodgers R.J., Blundell J.E., Ishii Y., Beattie A.H., Holch P., Allison D.B., Raun K., Madsen K., Wulff B.S., Stidsen C.E., Birringer M., Kreuzer O.J., Schindler M., Arndt K., Rudolf K., Mark M., Deng X.Y., Whitcomb D.C., Halem H., Taylor J., Dong J., Datta R., Culler M., Craney S., Flora D., Smiley D., and Heiman M.L. Physiology: does gut hormone PYY3-36 decrease food intake in rodents?. Nature 430 (2004) 1 p following 165; discussion 162 p following 165
102. Chan J.L., Mun E.C., Stoyneva V., Mantzoros C.S., and Goldfine A.B. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 14 (2006) 194-198
103. Alvarez Bartolome M., Borque M., Martinez-Sarmiento J., Aparicio E., Hernandez C., Cabrerizo L., and Fernandez-Represa J.A. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes. Surg. 12 (2002) 324-327
104. Borg C.M., le Roux C.W., Ghatei M.A., Bloom S.R., Patel A.G., and Aylwin S.J. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br. J. Surg. 93 (2006) 210-215
105. Strader A.D., Vahl T.P., Jandacek R.J., Woods S.C., D'Alessio D.A., and Seeley R.J. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E447-E453
106. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
107. Mojsov S., Heinrich G., Wilson I.B., Ravazzola M., Orci L., and Habener J.F. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J. Biol. Chem. 261 (1986) 11880-11889
108. Schirra J., Katschinski M., Weidmann C., Schafer T., Wank U., Arnold R., and Goke B. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J. Clin. Invest. 97 (1996) 92-103
109. Herrmann C., Goke R., Richter G., Fehmann H.C., Arnold R., and Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56 (1995) 117-126
110. Rocca A.S., and Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140 (1999) 1687-1694
111. Balks H.J., Holst J.J., von zur Muhlen A., and Brabant G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J. Clin. Endocrinol. Metab. 82 (1997) 786-790
112. Anini Y., Hansotia T., and Brubaker P.L. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 143 (2002) 2420-2426
113. Anini Y., and Brubaker P.L. Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells. Endocrinology 144 (2003) 3244-3250
114. Roberge J.N., and Brubaker P.L. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 128 (1991) 3169-3174
115. Kreymann B., Williams G., Ghatei M.A., and Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 (1987) 1300-1304
116. Verdich C., Toubro S., Buemann B., Lysgard Madsen J., Juul Holst J., and Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Int. J. Obes. Relat. Metab. Disord. 25 (2001) 1206-1214
117. Anini Y., and Brubaker P.L. Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes 52 (2003) 252-259
118. Verdich C., Flint A., Gutzwiller J.P., Naslund E., Beglinger C., Hellstrom P.M., Long S.J., Morgan L.M., Holst J.J., and Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 86 (2001) 4382-4389
119. Naslund E., King N., Mansten S., Adner N., Holst J.J., Gutniak M., and Hellstrom P.M. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br. J. Nutr. 91 (2004) 439-446
120. Ma X., Bruning J., and Ashcroft F.M. Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons. J. Neurosci. 27 (2007) 7125-7129
121. Mortensen K., Christensen L.L., Holst J.J., and Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept. 114 (2003) 189-196
122. Miyawaki K., Yamada Y., Ban N., Ihara Y., Tsukiyama K., Zhou H., Fujimoto S., Oku A., Tsuda K., Toyokuni S., Hiai H., Mizunoya W., Fushiki T., Holst J.J., Makino M., Tashita A., Kobara Y., Tsubamoto Y., Jinnouchi T., Jomori T., and Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8 (2002) 738-742
123. Sirinek K.R., O'Dorisio T.M., Hill D., and McFee A.S. Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery 100 (1986) 781-787
124. Clements R.H., Gonzalez Q.H., Long C.I., Wittert G., and Laws H.L. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am. Surg. 70 (2004) 1-4 (discussion 4-5)
125. Rubino F., Gagner M., Gentileschi P., Kini S., Fukuyama S., Feng J., and Diamond E. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann. Surg. 240 (2004) 236-242
126. Wren A.M., and Bloom S.R. Gut hormones and appetite control. Gastroenterology 132 (2007) 2116-2130
127. Dakin C.L., Gunn I., Small C.J., Edwards C.M., Hay D.L., Smith D.M., Ghatei M.A., and Bloom S.R. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142 (2001) 4244-4250
128. Dakin C.L., Small C.J., Batterham R.L., Neary N.M., Cohen M.A., Patterson M., Ghatei M.A., and Bloom S.R. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145 (2004) 2687-2695
129. Cohen M.A., Ellis S.M., Le Roux C.W., Batterham R.L., Park A., Patterson M., Frost G.S., Ghatei M.A., and Bloom S.R. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 88 (2003) 4696-4701
130. Wynne K., Park A.J., Small C.J., Patterson M., Ellis S.M., Murphy K.G., Wren A.M., Frost G.S., Meeran K., Ghatei M.A., and Bloom S.R. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54 (2005) 2390-2395
131. Wynne K., Park A.J., Small C.J., Meeran K., Ghatei M.A., Frost G.S., and Bloom S.R. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.) 30 (2006) 1729-1736
132. Little T.J., Horowitz M., and Feinle-Bisset C. Role of cholecystokinin in appetite control and body weight regulation. Obes. Rev. 6 (2005) 297-306
133. Stacher G., Bauer H., and Steinringer H. Cholecystokinin decreases appetite and activation evoked by stimuli arising from the preparation of a meal in man. Physiol. Behav. 23 (1979) 325-331
134. Burckhardt B., Delco F., Ensinck J.W., Meier R., Bauerfeind P., Aufderhaar U., Ketterer S., Gyr K., and Beglinger C. Cholecystokinin is a physiological regulator of gastric acid secretion in man. Eur. J. Clin. Invest. 24 (1994) 370-376
135. Fried M., Erlacher U., Schwizer W., Lochner C., Koerfer J., Beglinger C., Jansen J.B., Lamers C.B., Harder F., Bischof-Delaloye A., et al. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 101 (1991) 503-511
136. Beglinger C. Overview. Cholecystokinin and eating. Curr. Opin. Investig. Drugs 3 (2002) 587-588
137. Asin K.E., Gore Jr. P.A., Bednarz L., Holladay M., and Nadzan A.M. Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res. 571 (1992) 169-174
138. Beglinger C., Degen L., Matzinger D., D'Amato M., and Drewe J. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280 (2001) R1149-R1154
139. Kellum J.M., Kuemmerle J.F., O'Dorisio T.M., Rayford P., Martin D., Engle K., Wolf L., and Sugerman H.J. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann. Surg. 211 (1990) 763-770 (discussion 770-761)